North America Molecular Quality Controls Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)
North America Molecular Quality Controls Market: by Type (Independent Controls, Instrument-Specific Controls, Third-Party Controls), Application (Infectious Disease, Oncology, Genetics, Blood Screening, Microbiology, Others), Distribution Channels (Direct Sales, Distributors, Online Sales, Retail Pharmacies, Wholesalers, Others), Technology (PCR, NGS, Microarray, Isothermal Amplification, Mass Spectrometry, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025
Last Updated: 31-07-2025 | Format: PDF | Report ID:20365 | Author: Ankit
North America Molecular Quality Controls Market Outlook & Forecast (2025-2035)
The North America Molecular Quality Controls Market is set for robust growth through 2035, driven by technological advancements and expanding applications in clinical diagnostics. Innovations such as enhanced PCR and Next-Generation Sequencing (NGS) platforms are reshaping quality control standards, improving assay accuracy, and enabling early disease detection. The market's expansion is supported by the increasing need for compliance in regulated laboratory environments and the growing focus on personalized healthcare. Increasing investments, a surge in infectious disease testing, and genomics-based research across the US, Canada, and Mexico are setting the stage for sustained market development. Distribution diversification—through direct sales, e-commerce, and partnerships—bolsters market reach.
Latest Market Dynamics
Key Drivers
Rising incidence of infectious diseases and oncology, fueling demand for reliable molecular quality controls in clinical laboratories. For instance,
launched advanced molecular QC solutions to meet heightened accuracy needs in cancer screening in 2025.
Technological innovations, such as enhanced multiplex PCR and automation in quality controls, are driving laboratory efficiency. Roche Diagnostics, in early 2025, introduced an automated QC platform integrating AI analytics, expediting laboratory processes and improving result accuracy.
Key Trends
Shift towards third-party and customizable quality controls, as labs seek flexibility and interoperability. Bio-Rad Laboratories expanded its third-party QC portfolio in Q1 2025 to meet diverse laboratory requirements.
Increased adoption of digital health platforms in distribution, with companies like Abbott Laboratories integrating their QC products with cloud-based lab informatics for remote monitoring and compliance.
Key Opportunities
Expanding applications in genetic and blood screening, where demand for high-precision QCs is rising. Danaher Corporation in 2025 unveiled genetics-focused QC kits targeting North American reference labs.
Emergence of AI-driven analytics in QC data interpretation. LGC Limited partnered in 2025 with software firms to develop predictive QC monitoring, creating openings for value-added digital solutions.
Key Challenges
Cost barriers and reimbursement limitations, particularly for small and medium-sized clinical labs, restrict market access. Microbiologics is addressing this with cost-effective QC solutions aimed at community labs launched in early 2025.
Complex regulatory landscape imposing frequent changes. SeraCare Life Sciences published regulatory support guides in March 2025 to help labs maintain compliance amid evolving North American regulations.
Key Restraints
Lack of standardized QC protocols across regions leads to inconsistent lab practices. QuidelOrtho Corporation is advocating for unified QC standards through industry consortia in 2025.
Limited skilled workforce specializing in advanced molecular QC systems. Streck Inc. started training initiatives for lab technicians in 2025 to bridge the expertise gap and drive adoption.
North America Molecular Quality Controls Market Share by Type, 2025
In 2025, the North America Molecular Quality Controls Market is led by Independent Controls, which account for the majority share owing to their versatility across diverse platforms. Instrument-Specific Controls and Third-Party Controls also hold significant portions as laboratories seek specialized and interoperable solutions. Custom and internal/external controls present growing opportunities as laboratories increasingly look to tailor quality systems to their unique workflows and regulatory demands.
North America Molecular Quality Controls Market Share by Application, 2025
In 2025, Infectious Disease remains the dominant application segment, owing to sustained post-pandemic surveillance and routine pathogen screening. Oncology follows closely due to rising cancer diagnostic rates and genetic testing for personalized medicine. Blood Screening holds a substantial share, reflecting rising demand for safe transfusions and early disease detection. The increasing importance of genetics, microbiology, and other applications underlines the broadening scope of molecular quality controls in North American healthcare.
North America Molecular Quality Controls Market Revenue (USD Million), 2020-2035
Market revenue for North America Molecular Quality Controls is projected to expand from $520 Million in 2020 to $980 Million by 2025, reaching beyond $2600 Million by 2035. Growth is propelled by increasing clinical application, regulatory enforcement, and digital transformation in diagnostics. The revenue trajectory reflects accelerated adoption post-pandemic, with robust investments in automation and precision diagnostics expected to sustain high single-digit CAGR throughout the forecast period.
North America Molecular Quality Controls Market YOY (%), 2020-2035
Year-on-year growth rates for the North America Molecular Quality Controls Market will see an initial surge to 14% in 2025 as demand for advanced diagnostics peaks. Growth moderates to around 10% by 2030 and steadies at 7% through 2035 as the market matures, with expansion driven by ongoing innovation and the integration of molecular QC into routine clinical workflows.
North America Molecular Quality Controls Market Share by Region, 2025
In 2025, the United States dominates the North American molecular quality controls market, holding approximately 67% market share, attributed to advanced healthcare infrastructure, high research investments, and robust regulatory compliance. Canada follows with 21%, benefiting from continuous upgrades in diagnostic labs and increased genetic testing. Mexico is rapidly emerging with a 12% share as medical laboratory networks modernize and disease management programs expand.
North America Molecular Quality Controls Market Players Share, 2025
The competitive landscape in 2025 is led by Bio-Rad Laboratories with 23% of share, driven by a comprehensive QC product range and innovation leadership. Thermo Fisher Scientific and Roche Diagnostics hold 16% and 12% respectively, leveraging global networks and robust R&D investment. Other notable players include Danaher Corporation and Abbott Laboratories, while niche providers capture increasing specialty and regional market segments.
North America Molecular Quality Controls Market Share by Buyers, 2025
Clinical laboratories represent the largest buyer segment for molecular quality controls in North America, accounting for 49% of the market due to extensive routine and specialized diagnostic testing. Reference laboratories follow at 31%, leveraging high-throughput platforms for advanced disease detection and genetics. Hospital-based labs comprise 13%, while others include blood banks, biopharma, and CROs collectively forming the remainder.
June 2024: Bio-Rad Laboratories introduced a new multiplex infectious disease QC solution optimized for high-throughput labs.
July 2024: Abbott Laboratories expanded digital QC integration with leading laboratory information management systems (LIMS) in US facilities.
August 2024: SeraCare Life Sciences launched regulatory guideline support kits for molecular QC adaptation to U.S. and Canadian standards.
September 2024: Roche Diagnostics unveiled an AI-powered QC automation platform, enhancing result reliability for oncology diagnostics.
October 2024: Danaher Corporation announced a genetics-targeted QC product line with enhanced compatibility for next-generation sequencers.
Frequently Asked Questions
About the Author
Ankit
Senior Research Consultant
Ankit is a Senior Research Consultant specializing in market research, industry analysis, and business consulting across Healthcare. Ankit brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Ankit has helped organizations translate data into actionable growth strategies.
